- Sept. 18, 2019
-- Chemic Laboratories Inc. and Lifespan/ Rhode Island Hospital today announced establishment of a formal 12 month renewable Collaborative Agreement. As directed by the agreement Chemic Laboratories will provide RIH with select novel compounds discovered and developed by Chemic Laboratories. Dr. Eleftherios Mylonakis of RIH will oversee the design and execution of certain in vitro and in vivo investigations associated with H. pylori
"Chemic is delighted to enter into this formal agreement, Dr. Mylonakis is a pioneer in the study of infectious disease models and Chemic Laboratories is truly fortunate to be able to work with his team in assessing our unique compounds for activity against certain gram negative bacteria" said Joseph St. Laurent, President and CSO of Chemic Laboratories Inc. "This Agreement allows our groups to immediately move forward with studies designed over the last several months with the goal of enabling Chemic to select a primary candidate to move toward IND enablement".
Eleftherios Mylonakis, Chief of infectious diseases at Rhode Island Hospital and The Miriam Hospital in Providence, and Charles C.J. Carpenter Professor of Infectious Disease at the Warren Alpert Medical School of Brown University noted: "The World Health Organization (WHO) projects that by 2050, infections caused by resistant bacteria will surpass cancer as the global No. 1 killer. Unfortunately, most large pharmaceutical companies have abandoned this space and collaborations between academia and industry are needed to address this global need. We are particularly excited to expand this collaboration between RIH and Chemic Laboratories as these efforts will provide additional research opportunities between our molecular biologists and Chemic's medicinal chemists. These increased efforts have the potential to move drug candidates forward in a timely manner, and ultimately provide much needed treatment options for our patients." http://www.chemiclabs.com